2026年1月31日终止了Belite Bio的禁闭协议,允许内幕人士在61天的限制后出售股票。 A lock-up agreement for Belite Bio ended on Jan. 31, 2026, allowing insiders to sell shares after a 61-day restriction.

在2025年12月1日开始的61天限制之后,2026年1月31日终止了Belite Bio股份有限公司的禁闭协议。 A lock-up agreement for Belite Bio, Inc. ended on January 31, 2026, following a 61-day restriction that began December 1, 2025. 在此期间,公司经理和董事被禁止未经承保人同意出售或转让普通股份、美国保管股份或相关证券。 During this period, the company’s officers and directors were prohibited from selling or transferring ordinary shares, American Depositary Shares, or related securities without underwriters’ consent. 限制是公开报价条款的一部分,旨在通过限制内部股票销售来防止市场中断。 The restriction, part of the terms from a public offering, aimed to prevent market disruption by limiting insider share sales. 协议的缔结允许内幕人士根据正常证券规则出售股票。 The agreement’s conclusion allows insiders to potentially sell shares under normal securities rules.